Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

Cost-effectiveness analyses of genetic and genomic diagnostic tests

(2018) Katherine Payne et al.   NATURE REVIEWS GENETICS

The drug transporter OAT3 (SLC22A8) and endogenous metabolite communication via the gut–liver–kidney axis

(2017) Kevin T. Bush et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions

(2017) Hsin-Fang Wu et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children

(2017) Rajiv Balyan et al.   PHARMACOGENOMICS

Key Role for the Organic Anion Transporters, OAT1 and OAT3, in the in vivo Handling of Uremic Toxins and Solutes

(2017) Wei Wu et al.   Scientific Reports

OCT1 mediates hepatic uptake of sumatriptan and loss-of-functionOCT1polymorphisms affect sumatriptan pharmacokinetics

(2016) J Matthaei et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model

(2016) G Patilea-Vrana et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network

(2016) WS Bush et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Targeted Next-Generation Sequencing for Comprehensive Genetic Profiling of Pharmacogenes

(2016) SM Han et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin

(2016) S Goswami et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1

(2016) SW Yee et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs)

(2016) Peng Duan et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2016) Xiaodong Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters

(2016) Wendy A. Teft et al.   MOLECULAR PHARMACEUTICS

Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine

(2016) Kathleen M. Giacomini et al.   NATURE REVIEWS DRUG DISCOVERY

Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response

(2015) CC Wen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

More effective glycaemic control by metformin in African Americans than in Whites in the prediabetic population

(2015) C. Zhang et al.   DIABETES & METABOLISM

Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial

(2015) Mette Marie H. Christensen et al.   DIABETOLOGIA

The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion

(2015) Yumiko Akamine et al.   Drug Metabolism and Pharmacokinetics

Effect of genetic variations on ticagrelor plasma levels and clinical outcomes

(2015) Christoph Varenhorst et al.   EUROPEAN HEART JOURNAL

Polymorphisms inSLCO1B3andNR1I2as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination

(2015) Litaty Céphanoée Mbatchi et al.   PHARMACOGENOMICS

Exome sequencing and array-based comparative genomic hybridisation analysis of preferential 6-methylmercaptopurine producers

(2015) E W Chua et al.   PHARMACOGENOMICS JOURNAL

Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population-Modeling Approach

(2014) N Tsamandouras et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Design and Anticipated Outcomes of the eMERGE-PGx Project: A Multicenter Pilot for Preemptive Pharmacogenomics in Electronic Health Record Systems

(2014) L J Rasmussen-Torvik et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study

(2014) Tanja Dujic et al.   DIABETES

N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin–trimethoprim interaction

(2014) Fabian Müller et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients

(2014) Luciene Terezina de Lima et al.   Hematology

Differing Effects of Metformin on Glycemic Control by Race-Ethnicity

(2014) L. Keoki Williams et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Preemptive Genotyping for Personalized Medicine: Design of the Right Drug, Right Dose, Right Time—Using Genomic Data to Individualize Treatment Protocol

(2014) Suzette J. Bielinski et al.   MAYO CLINIC PROCEEDINGS

An atlas of genetic influences on human blood metabolites

(2014) So-Youn Shin et al.   NATURE GENETICS

Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk

(2014) Michael Gertz et al.   PHARMACEUTICAL RESEARCH

Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach

(2014) Nikolaos Tsamandouras et al.   PHARMACEUTICAL RESEARCH

Association of ABCC2 −24C>T Polymorphism with High-Dose Methotrexate Plasma Concentrations and Toxicities in Childhood Acute Lymphoblastic Leukemia

(2014) Yan Liu et al.   PLoS One

Organic Cation Transporter OCTs (SLC22) and MATEs (SLC47) in the Human Kidney

(2013) Hideyuki Motohashi et al.   AAPS Journal

Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration

(2013) Mladen V. Tzvetkov et al.   BIOCHEMICAL PHARMACOLOGY

Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG-CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism

(2013) Y Tomita et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms

(2013) K M Giacomini et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinically Actionable Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic Testing

(2013) SL Van Driest et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Reduced Renal Clearance of Cefotaxime in Asians with a Low-Frequency Polymorphism of OAT3 (SLC22A8)

(2013) Sook Wah Yee et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data

(2013) Joshua C Denny et al.   NATURE BIOTECHNOLOGY

Investigation of Endogenous Compounds for Assessing the Drug Interactions in the Urinary Excretion Involving Multidrug and Toxin Extrusion Proteins

(2013) Koji Kato et al.   PHARMACEUTICAL RESEARCH

Pharmacogenomics in early-phase clinical development

(2013) Tal Burt et al.   PHARMACOGENOMICS

Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation

(2013) N Fujimoto et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake

(2012) Min-Koo Choi et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction

(2012) Daniel I. Chasman et al.   Circulation-Cardiovascular Genetics

The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin

(2012) S L Stocker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients

(2012) Linda Tarasova et al.   Pharmacogenetics and Genomics

SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren

(2012) Tuija Tapaninen et al.   Pharmacogenetics and Genomics

The Expression and Function of Organic Anion Transporting Polypeptides in Normal Tissues and in Cancer

(2011) Amanda Obaidat et al.   Annual Review of Pharmacology and Toxicology

Genetically Polymorphic OCT1: Another Piece in the Puzzle of the Variable Pharmacokinetics and Pharmacodynamics of the Opioidergic Drug Tramadol

(2011) M V Tzvetkov et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Common 5′-UTR Variant in MATE2-K Is Associated With Poor Response to Metformin

(2011) J H Choi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects

(2011) H Kusuhara et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Association of ABCC2 Genotype with Efficacy of First-line FOLFIRI in Japanese Patients with Advanced Colorectal Cancer

(2011) Yuko Akiyama et al.   Drug Metabolism and Pharmacokinetics

Genetic Screening

(2011) W. Burke et al.   EPIDEMIOLOGIC REVIEWS

SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

(2011) Ming Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose

(2011) Ichiro Ieiri et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c

(2011) Mette M.H. Christensen et al.   Pharmacogenetics and Genomics

Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program

(2010) K. A. Jablonski et al.   DIABETES

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine

(2010) Zhi-Jun Wang et al.   Pharmacogenetics and Genomics

Very important pharmacogene summary

(2010) Laura M. Hodges et al.   Pharmacogenetics and Genomics

Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron

(2010) M V Tzvetkov et al.   PHARMACOGENOMICS JOURNAL

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity

(2009) K K Filipski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin

(2009) M V Tzvetkov et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Pharmacogenomics of Membrane Transporters Project: Research at the Interface of Genomics and Transporter Pharmacology

(2009) D L Kroetz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study

(2009) K. Zhou et al.   DIABETES

Functional Characterization of the Human Organic Cation Transporter 2 Variant p.270Ala>Ser

(2009) O. Zolk et al.   DRUG METABOLISM AND DISPOSITION

Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics

(2009) Federico Innocenti et al.   JOURNAL OF CLINICAL ONCOLOGY

Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy Humans

(2009) M. Muzi et al.   JOURNAL OF NUCLEAR MEDICINE

Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin

(2009) Ying Chen et al.   Pharmacogenetics and Genomics

Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus

(2009) M L Becker et al.   PHARMACOGENOMICS JOURNAL

Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin

(2008) IS Song et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Substrate-Dependent Effects of Human ABCB1 Coding Polymorphisms

(2008) J. M. Gow et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans

(2008) T. Watanabe et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes

(2008) I. S. Song et al.   XENOBIOTICA